NASDAQ:VYNE VYNE Therapeutics (VYNE) Stock Price, News & Analysis $2.09 -0.01 (-0.48%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.01▼$2.1350-Day Range$1.60▼$2.7352-Week Range$1.57▼$6.79Volume12,837 shsAverage Volume90,242 shsMarket Capitalization$30.37 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get VYNE Therapeutics alerts: Email Address VYNE Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside175.1% Upside$5.75 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.77) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.52 out of 5 starsMedical Sector520th out of 936 stocksPharmaceutical Preparations Industry238th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingVYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVYNE Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about VYNE Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.50% of the float of VYNE Therapeutics has been sold short.Short Interest Ratio / Days to CoverVYNE Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VYNE Therapeutics has recently increased by 10.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVYNE Therapeutics does not currently pay a dividend.Dividend GrowthVYNE Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VYNE. Previous Next 2.7 News and Social Media Coverage News SentimentVYNE Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for VYNE Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for VYNE on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of VYNE Therapeutics is held by insiders.Percentage Held by Institutions83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VYNE Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for VYNE Therapeutics are expected to decrease in the coming year, from ($0.77) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VYNE Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VYNE Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVYNE Therapeutics has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about VYNE Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About VYNE Therapeutics Stock (NASDAQ:VYNE)VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Read More VYNE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYNE Stock News HeadlinesJuly 20, 2024 | morningstar.comVYNE Therapeutics IncJune 26, 2024 | globenewswire.comVYNE Therapeutics to Participate in Leerink Partners Therapeutics ForumJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.June 13, 2024 | globenewswire.comVYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics on Promising Clinical Advancements and Strategic Pipeline ProgressionMay 9, 2024 | markets.businessinsider.comBuy Rating for VYNE Therapeutics on Strong Financial Footing and Promising Clinical PipelineMay 9, 2024 | investorplace.comVYNE Stock Earnings: VYNE Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comVYNE Reports First Quarter 2024 Financial Results and Provides Business UpdateJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.May 7, 2024 | finance.yahoo.comVYNE Therapeutics receives FDA approval for trial of VYN202May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics on Promising Drug Development Milestones and Positive Clinical DataMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics Amidst Favorable IND Clearance and Promising VYN202 DevelopmentMay 6, 2024 | globenewswire.comVYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET InhibitorMay 1, 2024 | globenewswire.comVYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual MeetingApril 13, 2024 | finance.yahoo.comVYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth PlansMarch 19, 2024 | finance.yahoo.comVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 19, 2024 | globenewswire.comVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 7, 2024 | seekingalpha.comWall Street Breakfast Podcast: NYCB Gets $1B Investment BoostSee More Headlines Receive VYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VYNE CUSIPN/A CIK1566044 Webvynetherapeutics.com Phone(800) 755-7936FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$5.75 High Stock Price Target$5.75 Low Stock Price Target$5.75 Potential Upside/Downside+181.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($5.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,450,000.00 Net Margins-6,874.47% Pretax Margin-6,737.83% Return on Equity-56.75% Return on Assets-48.81% Debt Debt-to-Equity RatioN/A Current Ratio13.02 Quick Ratio13.02 Sales & Book Value Annual Sales$420,000.00 Price / Sales70.57 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book0.32Miscellaneous Outstanding Shares14,530,000Free Float14,266,000Market Cap$29.64 million OptionableNot Optionable Beta1.32 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. David T. Domzalski (Age 57)CEO, President & Director Comp: $1.61MDr. Iain A. Stuart Ph.D. (Age 51)Chief Scientific Officer Comp: $856.82kMs. Mutya Harsch J.D. (Age 49)General Counsel, Chief Legal Officer & Company Secretary Comp: $817.97kMr. Tyler Zeronda (Age 37)CFO & Treasurer Dr. Darrell S. Rigel FAAD (Age 73)M.D., Consultant Comp: $40.2kKey CompetitorsKezar Life SciencesNASDAQ:KZRNextCureNASDAQ:NXTCHookipa PharmaNASDAQ:HOOKNuvectis PharmaNASDAQ:NVCTCybinNYSE:CYBNView All CompetitorsInsiders & InstitutionsAlphaCentric Advisors LLCSold 134,500 shares on 7/26/2024Ownership: 2.137%Virtu Financial LLCBought 16,199 shares on 5/20/2024Ownership: 0.112%Patrick G LeporeBought 13,000 shares on 11/15/2023Total: $50,830.00 ($3.91/share)View All Insider TransactionsView All Institutional Transactions VYNE Stock Analysis - Frequently Asked Questions How have VYNE shares performed this year? VYNE Therapeutics' stock was trading at $2.33 at the start of the year. Since then, VYNE stock has decreased by 10.3% and is now trading at $2.09. View the best growth stocks for 2024 here. How were VYNE Therapeutics' earnings last quarter? VYNE Therapeutics Inc. (NASDAQ:VYNE) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.09. The firm earned $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. VYNE Therapeutics had a negative net margin of 6,874.47% and a negative trailing twelve-month return on equity of 56.75%. When did VYNE Therapeutics' stock split? Shares of VYNE Therapeutics reverse split before market open on Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Who are VYNE Therapeutics' major shareholders? VYNE Therapeutics' top institutional investors include AlphaCentric Advisors LLC (2.14%). Insiders that own company stock include Patrick G Lepore, Mutya Harsch and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of VYNE Therapeutics? Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of VYNE Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Organigram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB) and Bionano Genomics (BNGO). This page (NASDAQ:VYNE) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.